Evidence map›Paper›PMID 37293441›Full record

ArticleBrain, behavior, & immunity - health2023

Neurophenotypes of COVID-19: Risk factors and recovery outcomes.

Divya Prabhakaran, Gregory S Day, Bala Munipalli, Beth K Rush, Lauren Pudalov, Shehzad K Niazi, Emily Brennan, Harry R Powers, Ravi Durvasula, Arjun Athreya and 1 more

Open access · goldAbstract read
In one paragraph

Article in Brain, behavior, & immunity - health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Review
  10. Effects of COVID-19 on cognition and brain health.Trends in cognitive sciences · 2023
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Divya PrabhakaranMayo Clinic, Center for Individualized Medicine, Jacksonville, FL, USA.
Gregory S DayMayo Clinic, Department of Neurology, Jacksonville, FL, USA.
Bala MunipalliMayo Clinic, Department of General Internal Medicine, Jacksonville, FL, USA.
Beth K RushMayo Clinic, Department of Psychiatry and Psychology, Jacksonville, FL, USA.
Lauren PudalovMayo Clinic, Department of Psychiatry and Psychology, Jacksonville, FL, USA.
Shehzad K NiaziMayo Clinic, Department of Psychiatry and Psychology, Jacksonville, FL, USA.
Emily BrennanMayo Clinic, Robert D. and Patricia E. Kern Center for the Science of Healthcare Delivery, Jacksonville, FL, USA.
Harry R PowersMayo Clinic, Division of Infectious Diseases, Jacksonville, FL, USA.
Ravi DurvasulaMayo Clinic, Division of Infectious Diseases, Jacksonville, FL, USA.
Arjun AthreyaMayo Clinic, Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, MN, USA.
Karen BlackmonMayo Clinic, Department of Psychiatry and Psychology, Jacksonville, FL, USA.
Jacksonville College · USWinnMed · USMayo Clinic in Florida · USMayo Clinic · USUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) infection is associated with risk of persistent neurocognitive and neuropsychiatric complications. It is unclear whether the neuropsychological manifestations of COVID-19 present as a uniform syndrome or as distinct neurophenotypes with differing risk factors and recovery outcomes. We examined post-acute neuropsychological profiles following SARS-CoV-2 infection in 205 patients recruited from inpatient and outpatient populations, using an unsupervised machine learning cluster analysis, with objective and subjective measures as input features. This resulted in three distinct post-COVID clusters. In the largest cluster (69%), cognitive functions were within normal limits, although mild subjective attention and memory complaints were reported. Vaccination was associated with membership in this "normal cognition" phenotype. Cognitive impairment was present in the remaining 31% of the sample but clustered into two differentially impaired groups. In 16% of participants, memory deficits, slowed processing speed, and fatigue were predominant. Risk factors for membership in the "memory-speed impaired" neurophenotype included anosmia and more severe COVID-19 infection. In the remaining 15% of participants, executive dysfunction was predominant. Risk factors for membership in this milder "dysexecutive" neurophenotype included disease-nonspecific factors such as neighborhood deprivation and obesity. Recovery outcomes at 6-month follow-up differed across neurophenotypes, with the normal cognition group showing improvement in verbal memory and psychomotor speed, the dysexecutive group showing improvement in cognitive flexibility, and the memory-speed impaired group showing no objective improvement and relatively worse functional outcomes compared to the other two clusters. These results indicate that there are multiple post-acute neurophenotypes of COVID-19, with different etiological pathways and recovery outcomes. This information may inform phenotype-specific approaches to treatment.

Identifiers

PMID37293441
PMCPMC10239310
OpenAlexW4379364854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.